MBI begins international trials of 3D scanner using CERN-adapted technology
What happened
MARS Bioimaging Ltd (MBI) is beginning large-scale international trials of its compact 3D-colour hand and wrist scanner. The scanner uses technology adapted from the European Organization for Nuclear Research (CERN). MBI established a research partnership with the universities of Canterbury and Otago. A 2019 feasibility study found the scanner provided significant improvements in diagnosing hand and wrist fractures compared to existing technology.
From nzdoctor.co.nz
Why it matters
The successful feasibility study and subsequent clinical trials validate the core product and revenue potential of MBI's scanner. The technology, which was developed in partnership with the universities of Canterbury and Otago, aims to improve the diagnosis of hand and wrist injuries.
From nzdoctor.co.nz
Who's involved
- MBICompany developing and distributing the 3D-colour scanner.
- CanterburyLocation of one of the partner universities.
- OtagoLocation of the partner university, University of Otago.
- Anthony ButlerPresident Medical Professor of MBI.
- University of OtagoPartner institution in the research and development.
- CERNInternational organization whose technology was adapted for the scanner.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- MBISpeculative
MBI could see its revenue potential validated by the successful feasibility study and international clinical trials.
Keep exploring
The entities involved
-
MBI
Chilean company specializing in the design, manufacture, and distribution of industrial and commercial products, particularly focusing on materials handling and storage solutions.
Nothing else this week.
-
Canterbury
cathedral city in Kent, England
-
Otago
New Zealand parliamentary electorate
Nothing else this week.